Clinical Trial Detail

NCT ID NCT03911557
Title Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors John L. Villano, MD, PhD
Indications

Advanced Solid Tumor

Therapies

Durvalumab + Tremelimumab

Age Groups: adult senior

Additional content available in CKB BOOST